Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas
[EN]Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of non-Hodgkin lymphomas frequently associated with poor prognosis and for which genetic mechanisms of transformation remain incompletely understood. Using RNA sequencing and targeted sequencing, here we identify a recurrent in-frame...
| Autores: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2017 |
| País: | España |
| Institución: | Universidad de Salamanca (USAL) |
| Repositorio: | GREDOS. Repositorio Institucional de la Universidad de Salamanca |
| OAI Identifier: | oai:gredos.usal.es:10366/168600 |
| Acceso en línea: | http://hdl.handle.net/10366/168600 |
| Access Level: | acceso abierto |
| Palabra clave: | VAV1 Gene fusion Mutation Peripheral T-cell lymphoma Lymphoma Sequence Deletion Base Sequence Humans Alternative Splicing Cell Line Guanine Proto-Oncogene Proteins c-vav Jurkat Cells Amino Acid Sequence Guanine Nucleotide Exchange Factors 3207.13 Oncología bio linfoma guanina factores de intercambio de nucleótidos de guanina deleción de secuencias humanos mutación proteínas protooncogénicas c-vav secuencia de aminoácidos secuencia de bases línea celular empalme alternativo células Jurkat |
| Sumario: | [EN]Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of non-Hodgkin lymphomas frequently associated with poor prognosis and for which genetic mechanisms of transformation remain incompletely understood. Using RNA sequencing and targeted sequencing, here we identify a recurrent in-frame deletion (VAV1 Δ778-786) generated by a focal deletion-driven alternative splicing mechanism as well as novel VAV1 gene fusions (VAV1-THAP4, VAV1-MYO1F, and VAV1-S100A7) in PTCL. Mechanistically these genetic lesions result in increased activation of VAV1 catalytic-dependent (MAPK, JNK) and non-catalytic-dependent (nuclear factor of activated T cells, NFAT) VAV1 effector pathways. These results support a driver oncogenic role for VAV1 signaling in the pathogenesis of PTCL. |
|---|